Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.57 USD | +4.02% | -14.48% | +248.00% |
Apr. 15 | Goldman Sachs Adjusts GeneDx Holdings Price Target to $11 From $6, Maintains Neutral Rating | MT |
Feb. 21 | Health Care Down on a Mixed Growth View -- Health Care Roundup | DJ |
Financials (USD)
Sales 2024 * | 226M | Sales 2025 * | 264M | Capitalization | 249M |
---|---|---|---|---|---|
Net income 2024 * | -136M | Net income 2025 * | -107M | EV / Sales 2024 * | 1.22 x |
Net Debt 2024 * | 27.09M | Net Debt 2025 * | 8.94M | EV / Sales 2025 * | 0.98 x |
P/E ratio 2024 * |
-1.96
x | P/E ratio 2025 * |
-2.77
x | Employees | 1,000 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.96% |
Latest transcript on GeneDx Holdings Corp.
1 day | +4.02% | ||
1 week | -14.48% | ||
Current month | +4.82% | ||
1 month | -0.93% | ||
3 months | +193.56% | ||
6 months | +174.21% | ||
Current year | +248.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 22-04-28 | |
Kevin Feeley
DFI | Director of Finance/CFO | 43 | - |
Paul Kruszka
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joshua Ruch
BRD | Director/Board Member | 74 | 21-07-21 |
Director/Board Member | 68 | 22-04-30 | |
Keith Meister
BRD | Director/Board Member | 51 | 20-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 9.57 | +4.02% | 156,304 |
24-04-17 | 9.2 | -4.27% | 171,348 |
24-04-16 | 9.61 | -2.73% | 98,237 |
24-04-15 | 9.88 | +2.70% | 190,201 |
24-04-12 | 9.62 | -14.03% | 184,474 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+248.00% | 249M | |
-18.11% | 8.02B | |
+36.93% | 3.51B | |
-26.72% | 2.97B | |
-7.36% | 2.48B | |
-14.48% | 2.23B | |
-14.89% | 1.76B | |
-23.12% | 1.44B | |
-39.19% | 1.25B | |
-10.74% | 1.11B |
- Stock Market
- Equities
- WGS Stock